Micromet, Inc. Reports Second Quarter 2009 Financial Results

... BiTE antibodies as well as Micromet's BiTE antibody MT110, which targets EpCAM, at the American ... data at the AACR meeting indicating that its BiTE antibody MT110 can direct T cells to eliminate ... an update to investors and analysts on its BiTE antibody pipeline and to review key AACR presentations. ...

PDL BioPharma Elects Barry Selick to Its Board of Directors

... as we seek to maximize the value of our antibody humanization patents and related assets and ... underlying the creation of fully humanized antibody therapeutics and applied this technology to PDL's ... PDL is focused on maximizing the value of its antibody humanization patents and related assets. The ...

PDL BioPharma Announces Second Quarter 2009 Financial Results

... PDL is focused on maximizing the value of its antibody humanization patents and related assets. The ... royalties on sales of a number of humanized antibody products marketed today and also may receive royalty payments on additional humanized antibody products launched before patent expiry in late ...

Immune responses to flu vaccine are diminished in lupus patients

... safe and do not increase disease activity. Both antibody and cell-mediated responses are involved in the immune response to influenza; in SLE, antibody responses to the vaccine are diminished, but it ... vaccination. Previous studies have shown that antibody production following flu vaccination is lower in ...

PDL BioPharma to Announce Second Quarter 2009 Financial Results and Hold Conference Call July 30, 2009

... PDL is focused on maximizing the value of its antibody humanization patents and related assets. The ... royalties on sales of a number of humanized antibody products marketed today and also may receive royalty payments on additional humanized antibody products launched before patent expiry in late ...

Amgen Announces KRAS Safety Update to U.S. Prescribing Information for Vectibix(R) (Panitumumab)

... colorectal cancer (mCRC) treated with anti-EGFr antibody was discussed. "We are pleased that the ... of KRAS as a predictive biomarker for anti-EGFr antibody therapy," said Sean Harper, M.D., chief medical ... respond to monotherapy with an EGFr-inhibiting antibody (the Vectibix "408" trial). "With this ...

New Drug Fights Anthrax Toxin

... in animals show that a new, monoclonal antibody drug might safely cure anthrax poisoning in ... journal editorial, said the paper shows that the antibody can block infection in animals and similar levels ... for efficacy in humans," Nabel said. This antibody provides a new tool to control anthrax infection ...

New Report Just Published: World Multiple Myeloma Therapeutics Market Report

... II-34 Immunotherapy II-34 Monoclonal antibody Treatment II-35 Vaccines II-35 Donor ... India II-46 ImmunoCellular Acquires Molecular antibody Technology II-46 US House of Representatives ... Favrille Announces Acquisition of Monoclonal antibody Range from Diversa II-52 Johnson & ...

Toronto researcher's discovery points to a new treatment avenue for acute myeloid leukemia

... has developed the first anti-cancer monoclonal antibody therapy that specifically targets cancer stem ... cause a recurrence of the disease. The antibody targets the CD123 protein (IL-3 receptor α ... cancer stem cells that drive cancer growth. The antibody does not appear to affect normal blood cells. On ...

Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1/2 Study of MM-111, a Bispecific Antibody to ErbB2/3

... (PK) of MM-111. MM-111 is the first bispecific antibody bindng two different receptors on the same cell ... pipeline candidate, MM-111 , a bispecific antibody fusion protein designed to target cancer cells ... known as HER2). MM-111 is the first bispecific antibody binding two different receptors on the same cell ...

Peregrine Pharmaceuticals Awarded Broad New U.S. Patent for Vascular Imaging Applications of Its PS-Targeting Platform

... platform, which includes Peregrine's lead antibody bavituximab. PS is a phospholipid that becomes ... Tumors in Rats with a Radioactive Arsenic-Labeled antibody that Binds Exposed Phosphatidylserine, Clinical ... and therapeutics. Bavituximab is a monoclonal antibody that specifically targets PS exposed on the ...

Phase 1 Study Initiated with Micromet Anti-GM-CS Human Antibody MT203

... colony-stimulating factor (GM-CSF) human antibody MT203 by its collaboration partner Nycomed. ... antibodies generated with its proprietary BiTE(R) antibody platform, as well as conventional monoclonal ... are currently in clinical trials. Its BiTE antibody blinatumomab (MT103) is in a phase 2 clinical ...

Elusys Therapeutics and Lonza Enter Into Manufacturing Agreement

... of Anthim(TM), a therapeutic monoclonal antibody in late stage development for the treatment of ... "Elusys has developed a very promising antibody therapeutic and we are proud to be able to ... humanized and deimmunized monoclonal antibody that targets the protective antigen of B. ...

PDL BioPharma Announces Record Date for October 1 Dividend Payment

... PDL is focused on maximizing the value of its antibody humanization patents and related assets. The ... royalties on sales of a number of humanized antibody products marketed today and also may receive royalty payments on additional humanized antibody products launched before patent expiry in late ...

Morphotek(R), Inc. Announces FDA Acceptance of Investigational New Drug Application for MORAb-004, a Monoclonal Antibody for the Treatment of Solid Tumors

... antibody Targets Endosialin, a Protein Widely Expressed on ... "MORAb-004 is another unique therapeutic antibody being developed by our company that is believed ... rights to develop and commercialize this antibody worldwide from the Ludwig Institute for Cancer ...

Strategic Diagnostics Appoints Kevin J. Bratton as Chief Financial Officer

... Diagnostics Inc. is a leading provider of antibody technology to the life science market place. ... By applying its core competencies of antibody and assay development, the Company produces unique, sophisticated reagents, reagent systems, antibody design services and biodetection solutions to ...

Amgen Highlights Data to Be Presented at ASCO

... 479, an investigational fully human monoclonal antibody antagonist of type 1 insulin-like growth factor ... reactions have occurred with other monoclonal antibody products. Stop infusion if a severe infusion ... Denosumab is the first fully human monoclonal antibody in late stage clinical development that ...

Micromet, Inc. Reports First Quarter 2009 Financial Results

... to develop and commercialize a specific BiTE antibody against an undisclosed solid tumor target. Bayer ... 2 clinical trial with its human anti-EpCAM IgG1 antibody adecatumumab (MT201). This randomized, ... Europe by its partner Nycomed for the anti-GM-CSF antibody MT203. The filing triggered a milestone payment ...

PDL BioPharma Appoints Karen J. Wilson as Vice President, Finance and Principal Accounting Officer

... PDL is focused on maximizing the value of its antibody humanization patents and related assets. The ... royalties on sales of a number of humanized antibody products marketed today, and also may receive royalty payments on additional humanized antibody products launched before patent expiry in late ...

Medarex Announces Clinical Data for MDX-1401 in Hodgkin's Lymphoma at Annual Meeting of the American Association for Cancer Research

... MDX-1401 is a fully human, non-fucosylated antibody that targets CD30, a marker for activated ... efficacy data for our second generation anti-CD30 antibody encouraging," said Geoffrey M. Nichol, MBChB, ... MDX-1401 is a second-generation anti-CD30 antibody where fucose (a sugar structure) is absent, ...

Medarex to Receive Milestone Payment for Approval of SIMPONI(TM) for the Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis

... - The second approved antibody generated from Medarex's UltiMAb(R) technology ... human anti-tumor necrosis factor (TNF) monoclonal antibody that was generated by Medarex's UltiMAb(R) ... sales of SIMPONI. "SIMPONI is the second antibody generated from our UltiMAb(R) technology to ...

Novavax Reports Fourth Quarter and 2008 Year-End Financial Results

... the vaccine demonstrated strong neutralizing antibody titers across all three doses tested, exhibiting increasing antibody titers with the escalation of the dose. The new ... (or "G" protein). The vaccine induced strong antibody responses against RSV and protected mice against ...

BioMosaics' Glypican-3 Antibody (clone 1G12) Validated at PhenoPath Laboratories for Immunohistochemical Detection of Liver Cancer

... company, announced today that its monoclonal antibody product (clone 1G12) for detection of Glypican-3 ... that PhenoPath has added the 1G12 Glypican-3 antibody to its test menu. Immunohistochemistry using this antibody provides added specificity to the identification ...

Medarex Highlights Oncology Pipeline at Needham Cancer Therapeutics Conference in New York City

... Ipilimumab is a fully human anti-CTLA-4 antibody in development for melanoma, prostate cancer and ... MDX-1342 is a fully human anti-CD19 antibody in Phase 1 development for chronic lymphocytic ... is a fully human non-fucosylated anti-CD30 antibody in Phase 1 development for Hodgkin Lymphoma. ...

New Yogurt May Ease Stomach Ulcers

... Japanese researchers say added antibody fights H. pylori bacteria MONDAY, ... of regular yogurt or yogurt fortified with the antibody IgY-urease. By comparison, people who'd eaten the ... than to take medication, especially since the antibody doesn't seem to alter the taste of the yogurt or ...

Morphotek(R), Inc. and Eisai Corporation of North America Announce FDA Special Protocol Assessment (SPA) for Phase III Trial Evaluating Farletuzumab in Relapsed Ovarian Cancer

... them most." Farletuzumab is a monoclonal antibody that binds to and blocks the function of folate ... cell surface antigens. Morphotek licensed the antibody and improved it using the company's proprietary ... specializing in the development of protein and antibody products through the use of a novel and ...

Lung cancer: Molecular scissors determine therapy effectiveness

... key molecules of tumor cells. Among these is an antibody called cetuximab, which attaches to a protein ... which reliably predict responsiveness to the antibody therapy. Professor Heike Allgayer heads the ... DKFZ. The scientist suspects that the therapeutic antibody can disarm, in particular, individual cancer ...

AnaptysBio Selects Gable PR of San Diego for National Communications Program During Key Phase in Growth

... AnaptysBio, Inc., a privately-held therapeutic antibody platform and product company seeking expanded ... -- AnaptysBio, Inc., a privately-held therapeutic antibody platform and product company, today announced it ... about the advantages of our platform for antibody discovery," said Tom Smart, AnaptysBio ...

Cephalon Launches Takeover Offer for Australian Biotechnology Company, Arana Therapeutics

... Offers Strong Technology Platform and Phase II antibody in Development for Inflammatory Diseases ... company focused on developing next generation antibody based drugs that will improve the lives of ... Its lead candidate, ART621, is a domain antibody currently in Phase II trials for both psoriasis ...

Flu virus foiled again

... as well. The study provides data about the antibody attachment site that are similar to the findings ... Holland (The Netherlands), discovered the potent antibody during a systematic examination of blood samples ... Through this process, the scientists found one antibody called CR6261 that had broad neutralizing ...

Medarex Announces 2008 Fourth Quarter and Year End Financial Results

... psoriasis antibody, the first approved antibody generated from our UltiMAb(R) technology ... Centocor's golimumab and Novartis' canakinumab antibody programs, which were also generated from our ... in Canada. STELARA represents to the first human antibody generated using Medarex's UltiMAb(R) technology ...

Scientists identify lab-made proteins that neutralize multiple strains of seasonal and pandemic flu

... The scientists also identified a new mechanism of antibody action against influenza: Once the antibody binds, the virus cannot change its shape, a step ... HA. Their detailed picture shows one arm of the antibody inserted into a genetically stable pocket in the ...

Tracon Pharmaceuticals to Present Clinical Stage Programs at AACR 2009

... TRC105 is a chimeric IgG1 monoclonal antibody that binds CD105, a membrane receptor required ... By inhibiting new blood vessel formation, the antibody is expected to have activity against a wide ... TRC093 is a humanized IgG1 monoclonal antibody that inhibits angiogenesis, tumor growth, and ...

Micromet To Present at the ROTH 21st Annual Orange County Growth Stock Conference

... and autoimmune diseases. The Company's novel antibody technology is based on its proprietary BiTE(R) antibody platform, representing a new class of antibodies ... development. The Company's lead program is a BiTE antibody known as blinatumomab, or MT103. It is in a phase ...

New test may help to ensure that dengue vaccines do no harm

... patient produces a large amount of the type of antibody that binds most strongly to the virus and that ... Fc end of antibodies, which brings whatever the antibody has locked onto into close contact with the cells ... cases, enabling the virus to break away from its antibody partner and begin copying itself. In this ...

New treatment hope for prostate cancer

... Xing said his group has produced a monoclonal antibody to a unique tumour marker for the treatment of prostate cancer. The monoclonal antibody is directed at cancer-producing cells carrying ... other cancers such as leukaemia. The monoclonal antibody significantly inhibited cancer cell growth when ...

Medarex to Receive Milestone Payment from MedImmune for Allowance of an Investigational New Drug Application for MEDI-546

... (IND) application for MEDI-546, a fully human antibody that targets a component of the type 1 interferon ... "This IND application marks the second antibody targeting the interferon inflammatory pathway ... commercialize a broad range of fully human antibody product candidates for itself and its partners. ...

GlaxoSmithKline and Genmab Submit Arzerra(TM) (Ofatumumab) Application to FDA for the Treatment of Advanced Stage Blood Cancer

... would be the first anti-CD20 monoclonal antibody available for this patient population. CLL ... Genmab. "This is the first BLA ever filed for an antibody produced by Genmab and is a significant ... Ofatumumab is an investigational monoclonal antibody that targets a membrane-proximal (close to the ...

New Data Published in Immunobiology Describe Mode of Action of BiTE Antibody MT110

... low amounts of Micromet's EpCAM-targeting BiTE antibody trigger the death of cancer cells BETHESDA, ... describing in detail the mode of action of BiTE antibody MT110 . MT110 is a T cell-engaging antibody that targets EpCAM, which is expressed with high ...

Medarex Reviews Recent Highlights and Outlook for 2009

... commercialize a broad range of fully human antibody product candidates for itself and its partners. ... value by developing a diverse pipeline of antibody products to address the world's unmet healthcare ... issues resulting from the administration of antibody products in patients, uncertainties related to ...